

Anti-RSPO2 Reference Antibody (OncoMed patent anti-RSPO2)

Catalog # APR11352

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q6UXX9
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	28315

Additional Information


Target/Specificity	RSPO2
Expression system	CHO

Protein Information


Name	RSPO2
Function	Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway (PubMed: 21727895 , PubMed: 21909076 , PubMed: 22615920). During embryonic development, plays a crucial role in limb specification, amplifying the Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3, hence governing the number of limbs an embryo should form (PubMed: 29769720).
Cellular Location	Secreted {ECO:0000250 UniProtKB:Q8BFU0}.

Images

Anti-RSPO2 Reference Antibody (OncoMed patent anti-RSPO2) on SDS-PAGE under reducing (R) condition.
The purity of the protein is greater than 95%.



The purity of Anti-RSPO2 Reference Antibody (OncoMed patent anti-RSPO2) is 98.75%, determined by SEC-HPLC.



Immobilized Hu-RSPO2-His at 5 µg/mL can bind OncoMed patent anti-RSPO2, EC50= 0.02972 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.